



Canada Health Infoway

Public Health Surveillance Community (PHSC)

October 3, 2024, 2:00–3:00 pm ET

PHS Community Agenda

1. Welcome and Introduction (5 min)
2. New Requests Since Last Meeting (5 min)
3. Prioritization of Work Items (40min)
4. Questions/Wrap Up (10 min)



Canada Health Infoway

1. Welcome and Introductions (5 min)

Myriam Talantikit, Canada Health Infoway



2. New Requests since last Meeting (5 min)

SNOMED CT

- 28 New concepts (8 Tradename, 18 antigens, 2 others)
- 9 New descriptions
- 7 Description changes

Myriam Talantikit, Canada Health Infoway

New Requests Since Last PHSC Meeting

FROM SEPTEMBER 2024 TO OCTOBER 2024 – NEW CONCEPT
(TRADENAME)

RFC	Status	Link
COMIRNATY messenger ribonucleic acid 30 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Completed	SCT-28988
COMIRNATY messenger ribonucleic acid 10 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Completed	SCT-28989
COMIRNATY messenger ribonucleic acid 10 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Completed	SCT-28990
COMIRNATY messenger ribonucleic acid 10 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Completed	SCT-28998
NUVAXOVID recombinant spike protein 5 micrograms per 0.5 milliliter suspension for injection Novavax Inc. (real clinical drug)	Completed	SCT-28999
COMIRNATY messenger ribonucleic acid 3 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Completed	SCT-29022
SPIKEVAX messenger ribonucleic acid 0.10 milligrams per 1 milliliter dispersion for injection Moderna Biopharma Canada Corporation (real clinical drug)	Completed	SCT-28987
IXCHIQ Chikungunya Vaccine, live, attenuated Powder for Solution for Intramuscular Injection Not less than 3.0 log ₁₀ TCID ₅₀ /0.5mL VALNEVA AUSTRIA GMBH	Completed	SCT-29016

New Requests Since Last PHSC Meeting

FROM SEPTEMBER 2024 TO OCTOBER 2024 – NEW CONCEPT

RFC	Status	Link
Antigen of Streptococcus pneumoniae Danish serotype 9N capsular polysaccharide conjugated (substance) Antigen of Streptococcus pneumoniae Danish serotype 17F capsular polysaccharide conjugated (substance) Antigen of Streptococcus pneumoniae Danish serotype 31 capsular polysaccharide conjugated (substance) Antigen of Streptococcus pneumoniae Danish serotype 23B capsular polysaccharide conjugated (substance) Antigen of Streptococcus pneumoniae Danish serotype 20A capsular polysaccharide conjugated (substance) Antigen of Streptococcus pneumoniae Danish serotype 15A capsular polysaccharide conjugated (substance) Antigen of Streptococcus pneumoniae Danish serotype 16F capsular polysaccharide conjugated (substance) Antigen of Streptococcus pneumoniae Danish serotype 35B capsular polysaccharide conjugated (substance) Antigen of Streptococcus pneumoniae Danish serotype 24F capsular polysaccharide conjugated (substance) Antigen of Streptococcus pneumoniae Danish serotype 23A capsular polysaccharide conjugated (substance)	Pending CA publication	SCT-29068 SCT-29067 SCT-29065 SCT-29062 SCT-29058 SCT-29054 SCT-29056 SCT-29066 SCT-29064 SCT-29060
Antigen of Streptococcus pneumoniae Danish serotype 16F capsular polysaccharide (substance) Antigen of Streptococcus pneumoniae Danish serotype 15A capsular polysaccharide (substance) Antigen of Streptococcus pneumoniae Danish serotype 35B capsular polysaccharide (substance) Antigen of Streptococcus pneumoniae Danish serotype 31 capsular polysaccharide (substance) Antigen of Streptococcus pneumoniae Danish serotype 24F capsular polysaccharide (substance) Antigen of Streptococcus pneumoniae Danish serotype 23B capsular polysaccharide (substance) Antigen of Streptococcus pneumoniae Danish serotype 23A capsular polysaccharide (substance) Antigen of Streptococcus pneumoniae Danish serotype 20A capsular polysaccharide (substance)	Pending CA publication	SCT-29024 SCT-29023 SCT-29030 SCT-29029 SCT-29028 SCT-29027 SCT-29026 SCT-29025
Product containing respiratory syncytial virus monoclonal antibody unspecified (product)	Completed	SCT-28969
Monoclonal antibody to Human Orthopneumovirus (substance)	Completed	SCT-29121

New Requests Since Last PHSC Meeting

FROM SEPTEMBER 2024 TO OCTOBER 2024 – NEW DESCRIPTION

RFC	Status	Link
60671000087102 - Add translation for SPIKEVAX messenger ribonucleic acid 0.10 milligrams per 1 milliliter dispersion for injection Moderna Biopharma Canada Corporation (real clinical drug)	Completed	SCT-29017
60681000087100 - Add translation for COMIRNATY messenger ribonucleic acid 30 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Completed	SCT-29018
60831000087103 - Add translation for COMIRNATY messenger ribonucleic acid 10 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Completed	SCT-29031
60841000087109 - Add translation for COMIRNATY messenger ribonucleic acid 10 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Completed	SCT-29032
60851000087107 - Add translation for NUVAXOVID recombinant spike protein 5 micrograms per 0.5 milliliter suspension for injection Novavax Inc. (real clinical drug)	Completed	SCT-29033
60891000087102 - Add translation for COMIRNATY messenger ribonucleic acid 3 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Completed	SCT-29048
60601000087107 - Add translation for CAPVAXIVE 0.5 milliliter solution for injection Merck Canada Inc. (real clinical drug)	Completed	SCT-28945
61241000087101 - Add translation for IXCHIQ not less than 3.0 log ₁₀ TCID ₅₀ per 0.5 milliliter powder for solution for injection Valneva Austria GmbH (real clinical drug)		SCT-29122
61231000087107 - Add translation for Product containing only monoclonal antibody to Human Orthopneumovirus (medicinal product)		SCT-29123

New Requests Since Last PHSC Meeting

FROM SEPTEMBER 2024 TO OCTOBER 2024 – CHANGE/RETIRE DESCRIPTION

RFC	Type	Status	Link
SPIKEVAX COVID-19 ancestral strain messenger ribonucleic acid 0.10 milligrams per 1 milliliter dispersion for injection Moderna Therapeutics Inc. (real clinical drug)	Change description	Completed	SCT-29011
COMIRNATY COVID-19 (original strain) messenger ribonucleic acid 30 micrograms per 0.3 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Change description	Completed	SCT-29015
COMIRNATY (original strain) messenger ribonucleic acid 10 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Change description	Completed	SCT-29019
COMIRNATY (original strain) messenger ribonucleic acid 3 micrograms per 0.2 milliliter suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Change description	Completed	SCT-29020
NUVAXOVID (original strain) recombinant spike protein 5 micrograms per 0.5 milliliter suspension for injection Novavax Inc. (real clinical drug)	Change description	Completed	SCT-29021
SPIKEVAX (original strain) messenger ribonucleic acid 0.20 milligrams per 1 milliliter dispersion for injection Moderna Biopharma Canada Corporation (real clinical drug)	Change description	Completed	SCT-29071
COMIRNATY (original strain) vaccine messenger ribonucleic acid 30 micrograms per 0.3 milliliter tris-sucrose formulation suspension for injection BioNTech Manufacturing GmbH (real clinical drug)	Change description	Completed	SCT-29072



Canada Health Infoway

3. Prioritization of Work Items (40 min)

Myriam Talantikit, Canada Health Infoway

Prioritization Of Working Items

The PHSC is invited to share what they see as higher to lower priority for the following known items that will require work from both the PHSC and Infoway

- 1. Patient-Friendly Picklist**
- 2. Enhanced Clinician Picklist (Preferred Terms review)**
- 3. Subset mergings**
 - TradeName, Historial, Antigen/Immunoglobulin
- 4. Antigen/Immunoglobulin content modification**


1. Patient-Friendly Picklist

What needs to be done?

- Confirm the CVC terms to be used – consensus
- Confirm the editorial guidelines alignment
 - Adjust the term that do not meet the guidelines alignment
- Prepare and submit RFCs
- Evaluate the Publication format options
- Publication and Maintenance process

	Generic –136 concepts	Tradename –183 concepts
Patient-Friendly Picklist	7 hours	2 hours

1. Patient-Friendly Picklist



2. Enhanced Clinical Picklist

What needs to be done?

- Confirm the PTs to be used – consensus (replace current PTs or use CVC)
 - Pattern to be confirmed
- Review and Adjust the term that do not meet the guidelines alignment
- Prepare and submit RFCs


	Generic –136 concepts	Tradename –183 concepts
Clinical Picklist	7 hours	2 hours

3. Subsets Merge


- What needs to be done?
 - Review options and their pros and cons
 - Determine options for identified challenges
 - Prepare and submit RFCs
 - Adjust editorial guidelines

	Estimated time
Subsets Merge	2 hours


Option 1: Create New subsets



Option 2: Merge current Tradename subsets and Historical Subsets



Option 3: Keep four current Tradename and Historical subsets



4. Antigen/ Immunoglobulin content modification

What needs to be done?

- Review options and their pros and cons
 - Publish content in a single refset?
- Confirm and review the requirements for the concepts to be used – consensus
 - Regardless of the publication options chosen
- Align the concepts with the requirements
- Review and Adjust the guidelines
- Prepare and submit RFCs

General Notes

- Small attendance during October meeting: 6 people
 - BC, NVC, PHO, CAN Immunize, PHAC represented
- Picklist
 - The details of Publication format will be discussed in more details during the working groups
 - Depending on what will be decided, a more clearer estimate of the time required can be determined
- Subset merge

Prioritization Of Working Items - Notes

➤ Prioritization was agreed with all present members as follow:

1. Picklists

➤ Patient-Friendly Picklist the most urgent

➤ Clinical Picklist

2. Antigen/Immunoglobulin content modification

3. Subsets merges

➤ Few organizations use CVC (BC) – Picklists (Patient-Friendly and Clinical) will be very important if a migration to NVC is decided

Prioritization Of Working Items - Notes

	Patient-Friendly Picklist	Clinician Picklist	Subsets mergings	Antigen & Immunoglobulin content modification
Priority	1	1	3	2
Deadline	Beginning of February to add it to the February Release	November? Depending on the feedback that will be received from the larger community	Current situation works for now-lowest priority	No deadline mentioned
Volunteers	EUDP NVC	EUDP		

Prioritization Of Working Items - Notes

- Etran mentioned that the deadline for Picklist is not as urgent for it to be integrated into the November release, as NVC will not be ready to integrate it before the New Year
- **ACTION ITEMS:**
 - Myriam: Reach out to the larger community to help defining Patient-Friendly
 - Information will be posted into the PHSC forum for feedback
 - Etran: to forward the forum message to her EUDP list to reach out the members



Canada Health Infoway

5. Questions/Wrap up

Next meeting

Thursday, November 7, 2024, 2:00-3:00 pm ET



Canada Health Infoway

Thank you!

Contact Information:

standards@infoway-inforoute.ca

VISIT OUR WEBSITE
infoway-inforoute.ca

VISIT OUR SURVEY WEBSITE
insights.infoway-inforoute.ca

LET'S CONNECT ON LINKEDIN
linkedin.com/company/canada-health-infoway

LET'S CONNECT ON TWITTER
@infoway